Phaseline

Companies › R-Pharm

R-Pharm: clinical trials, targets and expected readouts

6 active drug programs in 10 registered trials: 5 Phase 2, 3 Phase 3, 2 Phase 1; Oncology, Cardiovascular, Other, Immunology; next expected readout Apr 2027.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
Olokizumab
Interleukin-6 inhibitor
IL6Phase 3Polymyalgia Rheumatica; Lung Diseases, Interstitial; Juvenile Idiopathic ArthritisApr 2027
RPH-051
HER2-directed monoclonal antibody
ERBB2Phase 3Locally Advanced Breast CancerMay 2027
RPH-104
IL-6 receptor antagonist
IL6RPhase 3Idiopathic Recurrent Pericarditis; Familial Mediterranean FeverDec 2028
RS-113–Phase 2Metastatic Castration-resistant Prostate CancerMay 2027
Ocrelizumab (RPH-035)
B-lymphocyte antigen CD20 binding agent
MS4A1Phase 1Multiple SclerosisNov 2027
Panitumumab (RPH-030)
Epidermal growth factor receptor erbB1 inhibitor
EGFRPhase 1Metastatic Colorectal CancerAug 2028

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT05092776RPH-104Phase 2Familial Mediterranean FeverOtherJan 2025
NCT05673902RPH-104Phase 3Idiopathic Recurrent PericarditisCardiovascularJan 2026
NCT07670546OlokizumabPhase 3Polymyalgia RheumaticaImmunologyApr 2026
NCT06440746OlokizumabPhase 2Lung Diseases, InterstitialRespiratoryApr 2027
NCT07553988RS-113Phase 2Metastatic Castration-resistant Prostate CancerOncologyMay 2027
NCT07386938RPH-051Phase 3Locally Advanced Breast CancerOncologyMay 2027
NCT07597668Ocrelizumab (RPH-035)Phase 1Multiple SclerosisNeurologyNov 2027
NCT07543744Panitumumab (RPH-030)Phase 1Metastatic Colorectal CancerOncologyAug 2028
NCT05190991RPH-104Phase 2Familial Mediterranean FeverOtherDec 2028
NCT07517575OlokizumabPhase 2Juvenile Idiopathic ArthritisImmunologyJun 2030

Targets

EGFR (1) IL6R (1) ERBB2 (1) IL6 (1) MS4A1 (1)

Companies with the same targets

Roche Beijing Biotech AstraZeneca Shanghai Henlius Biotech Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Shanghai JMT-Bio Chia Tai Tianqing Pharmaceutical Group Yuhan Jiangsu HengRui Medicine Biocad

Companies built like this

Shanghai JMT-Bio BioRay Pharmaceutical Innovent Biopharmaceutical Technology (Hangzhou) Acerta Pharma Suzhou Zelgen Biopharmaceuticals

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.